Journal
ADVANCED HEALTHCARE MATERIALS
Volume 9, Issue 21, Pages -Publisher
WILEY
DOI: 10.1002/adhm.202000650
Keywords
bismuth; chemotherapy; hepatocellular carcinoma; radiotherapy; sorafenib
Funding
- National Natural Science Foundation of China [21501121, 81472673, 81672720, 81672334, 81760497, 81970505, 81960446]
- Natural Science Foundation of Shanghai [19ZR1434700]
- Natural Science Foundation of Xizang [XZ2019ZRG-117]
- Shanghai Science and Technology Commission [16ZR1406100]
Ask authors/readers for more resources
Sorafenib (SOR), a multi-kinase inhibitor for advanced hepatocellular carcinoma (HCC), reveals a limited therapeutic effect due to a lack of selectivity and evident drug resistance. In the present study, bismuth-based mesoporous nanomaterial (NBOF) is loaded with SOR and then coated with polyethylene glycol and folic acid conjugates (P-FA) to form an NBOF@SOR-P-FA nanocarrier system. The system achieves significantly enhanced anti-cancer efficacy by combining chemotherapy with radiotherapy. To evaluate the effect of synergistic treatment, cytotoxicity detection, Live/Dead staining, apoptotic assay, and Western blot analysis are performed. The results suggest that NBOF@SOR-P-FA significantly inhibits HCC cell proliferation and promotes cell apoptosis. Also, the NBOF@SOR-P-FA exhibits excellent biocompatibility by hemolysis and serum biochemical tests and produces a substantially enhanced contrast efficiency as compared to iohexol by computed tomography imaging. More importantly, the profound suppression of tumor growth and potentiation of apoptosis are observed in a mouse subcutaneous tumor model. Collectively, these results indicate that the bismuth-based nanotheranostic platform could enhance the therapeutic effect of sorafenib and serve as an innovative method for HCC treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available